Core Viewpoint - Xuan Bamboo Biotech-B (02575) saw its stock price increase by over 20%, reaching a new high of 93.05 HKD, driven by the inclusion of its innovative drug Xuan Yuen Ning in the national basic medical insurance drug list, enhancing affordability and accessibility for patients [1][1]. Company Developments - The recent announcement regarding Xuan Yuen Ning's inclusion in the national basic medical insurance drug list is expected to positively impact the company's long-term operational development by promoting market penetration and increasing sales scale [1][1]. - The company is positioned to benefit from the approval of two new oncology drugs by 2025, which are critical for realizing its innovative value [1][1]. Product Insights - The oncology drug pipeline includes Pirlosil with a differentiated indication targeting breast cancer, and Diroak, which offers high intracranial penetration and over 91% IC-ORR, addressing a gap in brain metastasis treatment [1][1]. - These products, along with Annelazole Sodium, form a "three-horse" commercial framework that lays a solid foundation for the company's long-term growth [1][1].
港股异动 | 轩竹生物-B(02575)涨超20%再破顶 轩悦宁进入医保目录 两款肿瘤产品年内密集获批